Global mRNA Vaccines & Therapeutics Market Growth 2023-2029

Global mRNA Vaccines & Therapeutics Market Growth 2023-2029

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
LPI (LP Information)' newest research report, the “mRNA Vaccines & Therapeutics Industry Forecast” looks at past sales and reviews total world mRNA Vaccines & Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected mRNA Vaccines & Therapeutics sales for 2023 through 2029. With mRNA Vaccines & Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Vaccines & Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global mRNA Vaccines & Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on mRNA Vaccines & Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global mRNA Vaccines & Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Vaccines & Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Vaccines & Therapeutics.
The global mRNA Vaccines & Therapeutics market size is projected to grow from US$ 35880 million in 2022 to US$ 11960 million in 2029; it is expected to grow at a CAGR of 11960 from 2023 to 2029.
Global core mRNA vaccines & therapeutics manufacturers include Moderna Therapeutics, CureVac etc. The top 3 companies hold a share about 65%. Europe is the largest market, with a share about 10%, followed by Asia Pacific and North America.
This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Vaccines & Therapeutics market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Infectious Disease Vaccines
Cancer Vaccines
Segmentation by application
Infectious Disease
Cancer
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology

Key Questions Addressed in this Report
What is the 10-year outlook for the global mRNA Vaccines & Therapeutics market?
What factors are driving mRNA Vaccines & Therapeutics market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do mRNA Vaccines & Therapeutics market opportunities vary by end market size?
How does mRNA Vaccines & Therapeutics break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.